preclamol

Known as: 3-PPP, Phenol, 3-(1-propyl-3-piperidinyl)-, n-N-propyl-3-(3-hydroxyphenyl)piperidine 
 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
1993
1993
Preclamol, the (-)enantiomer of 3-PPP (= 3(3-hydroxyphenyl)-N-n-propyl piperidine), has a selective dopamine autoreceptor- and… (More)
Is this relevant?
1992
1992
The dopamine (DA) autoreceptor agonist (−)-3PPP (preclamol) was tested in male schizophrenic volunteers for safety. The drug was… (More)
  • table 1
  • figure 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
1992
1992
The effects of the high affinity sigma (σ) ligands 1,3-di(2-tolyl)guanidine (DTG), (+)N-cyclopropylmethyl-N-methyl-1,4-diphenyl-1… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • table 1
Is this relevant?
1987
1987
Raclopride, a new potential antipsychotic agent blocking central dopamine (D2) receptors, was found to suppress exploratory… (More)
Is this relevant?
1986
1986
The effects of two proposed dopaminergic autoreceptor agonists, (-)3-(3-hydroxyphenyl)-N-n-propylpiperidine (3-PPP) and the… (More)
Is this relevant?
1986
1986
A behavioral study was performed in an attempt to understand the neuronal mechanisms involved in yawning behavior in rats… (More)
  • figure 1
Is this relevant?
1985
1985
Extracellular single unit recording and micro-iontophoretic studies were carried out in chloral hydrate-anesthetized and… (More)
  • figure 1
  • figure 3
  • table 1
  • figure 6
  • figure 7
Is this relevant?
Highly Cited
1984
Highly Cited
1984
Neuroleptics such as thioxanthenes (cis(Z)-flupentixol and cis(Z)-clopenthixol) and phenothiazines (fluphenazine and perphenazine… (More)
Is this relevant?
1984
1984
Both enantiomers of the dopamine analogue 3-(3-hydroxyphenyl)-N-n-propylpiperidine (3-PPP; 0.5-32 mg/kg s.c.) dose dependently… (More)
Is this relevant?
1983
1983
3-(3-Hydroxyphenyl)-N-n-propylpiperidine (3-PPP) is a novel compound existing in two enantiomers which, as judged by recent… (More)
Is this relevant?